The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)/2D/3D culture models harboring EGFR amplification and CDKN2A/2B homozygous deletions

Non-small cell lung cancer (NSCLC) patients without targetable driver mutation have limited treatment options. In this study, we aimed to explore a new therapeutic strategy by using established nine patient-derived xenograft (PDX) and two-dimensional (2D) /3D culture models with specific genetic alt...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jen-Fen Fu, Cheng-Lung Hsu, Ping-Chih Hsu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-11-01
coleção:	Neoplasia: An International Journal for Oncology Research
Assuntos:	Non-small cell lung cancer, Wildtype EGFR amplification, CDKN2A/2B homozygous deletions, PDX/2D/3D cell model, Osimertinib Palbociclib
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1476558624000812
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!